Patrick Lamy - 28 Jun 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Reporting relationship: Senior VP, Commercial Strategy
Issuer ticker: AKRO
Reported as of: 28 Jun 2024
Net transaction value: +$4,407
SEC form: 4
Accepted by SEC: 02 Jul 2024, 18:56:16 UTC
Prior SEC filing: 13 Jun 2024
Next SEC filing: 12 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Young, Attorney-in-Fact

Key filing fact

Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 02 Jul 2024.

Key facts

This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2024, 18:56.

Change

Previous filing in this sequence was filed on 13 Jun 2024.
Current net transaction value: +$4,407.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKRO transaction

Common Stock

Award

Transaction value: $4,407
Shares: +221
Change %: +1.2%
Price: $19.94
Shares after: 18,783
Date: 28 Jun 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Mr. Lamy is voluntarily reporting the acquisition of these shares on June 28, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).

Footnote F2

In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on June 28, 2024.